mex-3 RNA binding family member AGenealiases: MEX-3A · RKHD4 · RNF162
Q-omics provides the consensus-scored MEX3A profile across patient tissues and cancer cell-line models. MEX3A expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MEX3A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MEX3A RNA expression shows 23,335 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where MEX3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEX3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEX3A survival associations across molecular data types. MEX3A RNA expression shows survival associations in the most cancer types (30), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEX3A RNA expression–survival associations across cancer types. High MEX3A expression shows unfavorable associations in ACC, MESO, LIHC, UVM and KIRC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MEX3A RNA expression.
This table summarizes MEX3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MEX3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEX3A shows higher tumor expression in BLCA, COAD, LUAD, STAD, LUSC and LIHC. The BLCA box plot shows higher MEX3A RNA expression in tumor versus normal tissue (log2 FC = +3.667, t-test p < 0.001).
This table shows molecular features associated with MEX3A in patient tissues and cancer cell lines. In patient samples, MEX3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEX3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
